Bristol Myers Squibb presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. EXPLORER-LTE is… read more.
Wearable sensors coupled with AI can generate blood pressure readings nearly as well as the invasive and risky arterial lines relied on in intensive care units and operating… read more.
Intensive, long-term blood pressure-lowering treatment reduced the risk of recurrent stroke by 38%, without increasing serious adverse events, in people who have survived an intracerebral haemorrhage (ICH). The… read more.
An international study has found that despite two decades of global tobacco control efforts, the message still is not getting through to enough smokers that smoking and second-hand… read more.
Capricor Therapeutics announced that the FDA has extended the Prescription Drug User Fee Act (PDUFA) target action date for its Biologics License Application (BLA) for Deramiocel, an investigational… read more.
Older adults with cardiovascular disease (CVD) often have coexisting cognitive impairment and frailty, conditions that can significantly affect treatment decisions, recovery, independence and quality of life and should… read more.
A postpartum care model combining health coaching with self-measured blood pressure (BP) monitoring significantly improved both health care engagement and blood pressure control by 12 months post partum,… read more.
Having high blood pressure is associated with greater intentions to follow doctors’ recommendations to take medication than people without high blood pressure but lesser intentions to make recommended… read more.
NICE: Finerenone can be used, within its marketing authorisation, as an option to treat symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults. Why… read more.
Medtronic announced an expanded CE Mark indication for the Affera Mapping and Ablation System with Sphere-9 Catheter to treat ventricular arrhythmias, including ventricular tachycardia (VT) and premature ventricular… read more.
NICE (UK): Aficamten can be used as an option to treat symptomatic obstructive hypertrophic cardiomyopathy in adults with a New York Heart Association class of 2 to 3…. read more.
Cytokinetics, Incorporated announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted MYQORZO (aficamten) a marketing authorisation across the United Kingdom for the treatment of symptomatic… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
